Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS)

Seminars in Oncology

Volumn 32, Issue SUPPL. 5, 2005, Pages 31-35

  List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; IMMUNOMODULATING AGENT; LENALIDOMIDE; RECOMBINANT ERYTHROPOIETIN;

5Q- SYNDROME; ANGIOGENESIS; BLAST TRANSFORMATION; BONE MARROW SUPPRESSION; BURST FORMING UNIT; CHROMOSOME ABERRATION; CLINICAL FEATURE; CYTOKINE PRODUCTION; DIARRHEA; DOWN REGULATION; DRUG EFFECT; FATIGUE; HUMAN; KARYOTYPE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; TH1 CELL; TH2 CELL; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THYROID DISEASE; URTICARIA;

EID: 23444462111     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.06.020     Document Type: Article

References (30)

1. A.F. List New approaches to the treatment of myelodysplasia Oncologist 7 suppl 1 2002 39 49
2. W.-K. Hofmann, M. Lübbert, D. Hoelzer Myelodysplastic syndromes Hematol J 5 2004 1 8
3. D. Bowen, D. Culligan, S. Jowitt Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes Br J Haematol 120 2003 187 200
4. C. Rosenfeld, A. List A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies Leukemia 14 2000 2 8
5. G. Pruneri, F. Bertolini, D. Soligo Angiogenesis in myelodysplastic syndromes Br J Cancer 81 1999 1398 1401
6. A. Aguayo, H. Kantarjian, T. Manshouri Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes Blood 96 2000 2240 2245
7. J.W. Hussong, G.M. Rodgers, P.J. Shami Evidence of increased angiogenesis in patients with acute myeloid leukemia Blood 95 2000 309 313
8. S. Kumar, T.E. Witzig, A. Dispenzieri Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma Leukemia 18 2004 624 627
9. S. Faderl, H.M. Kantarjian Novel therapies for myelodysplastic syndromes Cancer 101 2004 226 241
10. List AF: Emerging data with IMiDs in the treatment of MDS. 9th Annual Congress of the European Hematology Association; Geneva, Switzerland; June 10, 2004
11. A. List, S. Kurtin, D.J. Roe Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 2005 549 557
12. J.B. Bartlett, K. Dredge, A.G. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 2004 314 322
13. P. Musto Thalidomide therapy for myelodysplastic syndromes: Current status and future perspectives Leuk Res 28 2004 325 332
14. L.G. Corral, P.A. Haslett, G.W. Muller Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α J Immunol 163 1999 380 386
15. A.K. Gandhi, S. Naziruddin, D. Verhelle Anti-proliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines J Clin Oncol 22 suppl 14S 2004 587s (abstr 6618)
16. S. Miyamoto, H. Teramoto, O.A. Coso Integrin function: Molecular hierarchies of cytoskeletal and signaling molecules J Cell Biol 131 1995 791 805
17. S.L. Bellis, J.A. Perrotta, M.S. Curtis Adhesion of fibroblasts to fibronectin stimulates both serine and tyrosine phosphorylation of paxillin Biochem J 325 1997 375 381
18. D.W. Leung, G. Cachianes, W.J. Kuang Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1989 1306 1309
19. H. Birkedal-Hansen Proteolytic remodeling of extracellular matrix Curr Opin Cell Biol 7 1995 728 735
20. H.F. Dvorak, L.F. Brown, M. Detmar Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis Am J Pathol 146 1995 1029 1039
21. W.T. Bellamy, L. Richter, D. Sirjani Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes Blood 97 2001 1427 1434
22. R.J. D'Amato, M.S. Loughnan, E. Flynn Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 91 1994 4082 4085
23. K. Dredge, J.B. Marriott, C.D. Macdonald Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects Br J Cancer 87 2002 1166 1172
24. S. Lentzsch, M.S. Rogers, R. LeBlanc S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice Cancer Res 62 2002 2300 2305
25. S. Lentzsch, R. LeBlanc, K. Podar Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Leukemia 17 2003 41 44
26. A. Raza, P. Meyer, D. Dutt Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Blood 98 2001 958 965
27. C. Strupp, U. Germing, M. Aivado Thalidomide for the treatment of patients with myelodysplastic syndromes Leukemia 16 2002 1 6
28. J.M. Bennett, D. Catovsky, M.T. Daniel Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 1982 189 199
29. P. Greenberg, C. Cox, M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 91:1100, 1998] Blood 89 1997 2079 2088
30. B.D. Cheson, J.M. Bennett, H. Kantarjian Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 96 2000 3671 3674